arrow
L

Lídia Sabater

centro de investigación biomédica en red de enfermedades raras
H指数:57
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MicroRNA and Inflammatory Biomarker Signatures Associated With Neurological Outcome After Out-Of-Hospital Cardiac Arrest: The MiRacle Study

微RNA和炎症生物标志物特征与院外心脏骤停后神经功能结局的关联:MiRacle研究

2026-09-070
OAAI
Relapses, Comorbidities, and Predictors of Outcome in Anti-GABAA Receptor Encephalitis

复发、共病及抗GABAA受体脑炎预后的预测因素

2026-04-120
OAAI
Brainstem pathology in anti-IgLON5 disease: new insights into early events and tau progression

抗-IgLON5病中的脑干病理:对早期事件和tau蛋白进展的新见解

Brain
IF11.7
2026-04-011
PRE
Cytokine and Chemokine Profiles in Anti-LGI1 Encephalitis Markers of Severity and Outcome
2025-11-010
PRE
Brain atrophy patterns in anti-IgLON5 disease

抗IgLON5病中的脑萎缩模式

Brain
IF11.7
2025-07-120
OAAI
Frequency, characteristics, and immunological accompaniments of ataxia in anti-NMDAR antibody-associated encephalitis

抗NMDAR抗体相关性脑炎中共济失调的频率,特征和免疫学伴随

2024-12-130
OAAI
Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy

anti-IgLON5疾病的神经病理谱和脑干tau病理分期: 疾病相关tau病的最新神经病理研究标准

2024-10-140
OAAI
Antibodies Against ZSCAN1 in Pediatric and Adult Patients With Non-Paraneoplastic ROHHAD Syndrome

儿童和成人非副肿瘤rohhard综合征患者的ZSCAN1抗体

2024-09-013
OAAI
HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease
2024-05-162
OAAI
HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease

HLA-DQB1 * 05亚型而非DRB1 * 10:01介导anti-IgLON5疾病的风险

BRAIN
IF11.7
2024-03-019
PRE
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis

mRNA新型冠状病毒肺炎疫苗接种不会加剧多发性硬化症的症状或触发神经抗体反应

2023-11-014
OAAI
Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease

九例anti-IgLON5患者尸检中炎症标志物和tau沉积物的分析

2023-08-3019
OA